KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Long-Term Investments (2017 - 2023)

Pacira BioSciences has reported Long-Term Investments over the past 10 years, most recently at $2.4 million for Q4 2023.

  • For Q4 2023, Long-Term Investments fell 93.52% year-over-year to $2.4 million; the TTM value through Dec 2023 reached $2.4 million, down 93.52%, while the annual FY2023 figure was $2.4 million, 93.52% down from the prior year.
  • Long-Term Investments for Q4 2023 was $2.4 million at Pacira BioSciences, down from $8.3 million in the prior quarter.
  • Over five years, Long-Term Investments peaked at $70.6 million in Q3 2019 and troughed at $2.4 million in Q4 2023.
  • A 5-year average of $23.1 million and a median of $15.7 million in 2020 define the central range for Long-Term Investments.
  • Biggest five-year swings in Long-Term Investments: skyrocketed 1484.13% in 2019 and later crashed 93.52% in 2023.
  • Year by year, Long-Term Investments stood at $11.0 million in 2019, then increased by 27.78% to $14.0 million in 2020, then soared by 149.45% to $35.0 million in 2021, then grew by 6.4% to $37.2 million in 2022, then crashed by 93.52% to $2.4 million in 2023.
  • Business Quant data shows Long-Term Investments for PCRX at $2.4 million in Q4 2023, $8.3 million in Q1 2023, and $37.2 million in Q4 2022.